State Key Laboratory of Oral Disease & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
Department of Pediatric Dentistry, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
J Oral Pathol Med. 2023 Aug;52(7):583-592. doi: 10.1111/jop.13418. Epub 2023 Mar 19.
Oral tongue squamous cell carcinoma tends to metastasize to cervical lymphatic nodes early which leads to a 50% drop of survival rate. CXCL1 could be secreted by LNMTca8113 cell induced lymphatic endothelial cells and promoted LNMTca8113 cell migration. The current study aimed to further explore the effect of CXCL1 on the proliferation and migration abilities of tongue cancer cells and the prognostic value of serum CXCL1 in oral tongue squamous cell carcinoma.
Cell proliferation and migration ability were analysed by CCK8 assays and transwell migration assays. Immunofluorescence technique was used to show cytoskeleton. GST pull-down assay was applied to quantify the activation of GTPases. Blood samples of patients were collected and clinicopathological characteristics were analysed.
CXCL1 could promote cancer cell proliferation in appropriate concentration by PI3K/AKT pathway. It also regulated the activation of Rho GTPases to mediate the rearrangements of cytoskeleton to promote tumour cell migration. Level of plasma CXCL1 could predict the possibility of early lymphatic metastasis and had a predictive value in progression-free survival and overall survival.
CXCL1 could promote oral cancer cell proliferation, migration and invasion in vitro and contributed theoretical knowledge for the target selection in molecular targeted therapy. Level of plasma CXCL1 might serve as a biomarker for prognosis in oral tongue squamous cell carcinoma patients.
口腔舌鳞状细胞癌往往较早转移到颈部淋巴结,导致生存率下降 50%。CXCL1 可由 LNMTca8113 细胞诱导的淋巴管内皮细胞分泌,并促进 LNMTca8113 细胞迁移。本研究旨在进一步探讨 CXCL1 对舌癌细胞增殖和迁移能力的影响,以及血清 CXCL1 在口腔舌鳞状细胞癌中的预后价值。
通过 CCK8 检测和 Transwell 迁移实验分析细胞增殖和迁移能力。免疫荧光技术用于显示细胞骨架。应用 GST 下拉实验来定量测定 GTPases 的激活。收集患者的血液样本,并分析临床病理特征。
CXCL1 可通过 PI3K/AKT 通路在适当浓度下促进癌细胞增殖。它还调节 Rho GTPases 的激活,以介导细胞骨架的重排,从而促进肿瘤细胞迁移。血浆 CXCL1 水平可预测早期淋巴转移的可能性,并对无进展生存期和总生存期具有预测价值。
CXCL1 可促进口腔癌细胞在体外的增殖、迁移和侵袭,为分子靶向治疗的靶点选择提供了理论知识。血浆 CXCL1 水平可能可作为口腔舌鳞癌患者预后的生物标志物。